ENOV (Enovis) Other Long-Term Liabilities: $369 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ENOV Enovis Corp ENOV
68 GF Score
Price $26.06
GF Value $45.10
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Enovis Other Long-Term Liabilities?

Enovis ENOV -0.46% 68 Other Long-Term Liabilities is $369 Mil as of Jun. 2026. GuruFocus rates ENOV with a GF Score™ of 68/100 and a GF Value™ of $45.10 (Possible Value Trap). The stock has 6 warning signs investors should review.

Enovis's other long-term liabilities for the quarter that ended in Jun. 2026 was $369 Mil.

Enovis's quarterly other long-term liabilities declined from Dec. 2025 ($425 Mil) to Mar. 2026 ($394 Mil) and declined from Mar. 2026 ($394 Mil) to Jun. 2026 ($369 Mil).

Enovis's annual other long-term liabilities increased from Dec. 2023 ($204 Mil) to Dec. 2024 ($264 Mil) and increased from Dec. 2024 ($264 Mil) to Dec. 2025 ($425 Mil).

Enovis Other Long-Term Liabilities Related Terms

Enovis Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Enovis's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enovis Other Long-Term Liabilities Chart

Enovis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 695.72 166.99 204.18 263.52 424.57

Enovis Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 450.56 437.01 424.57 393.81 368.63
ENOV
68GF Score
Enovis Corp ENOV
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enovis Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $369 Mil mean?
Enovis (ENOV) has a Other Long-Term Liabilities of $369 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Enovis and its competitors.
Is Enovis' Other Long-Term Liabilities too high?
Enovis' current Other Long-Term Liabilities is $369 Mil. Overall, Enovis has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Enovis' Other Long-Term Liabilities compare to IART and AHCO?
Enovis' Other Long-Term Liabilities of $369 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Medical Devices & Instruments company?
A good Other Long-Term Liabilities depends on the Medical Devices & Instruments industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Enovis and its competitors. Enovis's current Other Long-Term Liabilities is $369 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enovis stock overvalued right now?
Based on GuruFocus' analysis, Enovis (ENOV) is currently considered Possible Value Trap. The stock's GF Value™ is $45.10, compared to a current price of $26.06 — trading 42.2% below its estimated fair value. The current Other Long-Term Liabilities is $369 Mil. Enovis' overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Enovis (ENOV), the current Other Long-Term Liabilities is $369 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enovis (ENOV) Overvalued in 2026?

Based on GuruFocus' analysis, Enovis stock appears to be undervalued. The current stock price of $26.06 is trading 42.2% below its estimated GF Value™ of $45.10. GuruFocus considers Enovis to be Possible Value Trap.

Key valuation signals for ENOV:

  • Other Long-Term Liabilities: $369 Mil
  • GF Value™: $45.10 vs. price of $26.06 (42.2% below fair value)
  • GF Score™: 68/100 with 6 warning signs

No single metric tells the full story. See the ENOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enovis Business Description

Address 2711 Centerville Road, Suite 400, Wilmington, DE, USA, 19808
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
68GF Score

Get the complete analysis for ENOV

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.06
Price
$45.10
GF Value